STAT+: Administration report on most favored nation drug pricing raises new details — and questions

The Trump administration released a report on its drug pricing policy, claiming huge future savings from the program, with an estimated $529 billion in savings over the coming decade. The report defines 'most-favored nation' pricing, a key aspect of the administration's deals with pharmaceutical companies. However, many details of the deals remain private and their impacts for consumers are uncertain.